Renal Failure News and Research RSS Feed - Renal Failure News and Research

Renal failure or kidney failure is where the kidneys fail to function adequately. Renal failure is divided in acute and chronic forms; either form may be due to a large number of other medical problems.
3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the entire equity interest in Zhejiang Wansheng Pharmaceutical Co., Ltd a limited liability company incorporated in the PRC for an aggregate consideration of RMB 528 million. [More]
Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Amgen today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Kyprolis (carfilzomib) for Injection to seek an expanded indication for the treatment of patients with a form of blood cancer, relapsed multiple myeloma, who have received at least one prior therapy. [More]
Sepsis readmissions have significant impact on health care expenditures in California

Sepsis readmissions have significant impact on health care expenditures in California

The Affordable Care Act created several national initiatives aimed at reducing hospital readmission rates for heart attacks, congestive heart failure and other common high-risk conditions. But there is still no national program intended to address sepsis, a potentially life-threatening illness caused by infection. [More]
Tests reveal that FY26 cancer drug is 49 times more potent than Cisplatin drug

Tests reveal that FY26 cancer drug is 49 times more potent than Cisplatin drug

Tests have shown that a new cancer drug, FY26, is 49 times more potent than the clinically used treatment Cisplatin. [More]
3SBio obtains ex-China global rights to Apexigen's anti-TNF mAb technology

3SBio obtains ex-China global rights to Apexigen's anti-TNF mAb technology

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the ex-China global rights to Apexigen's anti-TNF monoclonal antibody ("mAb") technology. 3SBio previously acquired the China rights from Apexigen in 2006. [More]
Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Amgen today announced that a Phase 3 study evaluating Vectibix (panitumumab) and best supportive care (BSC) met its primary endpoint, demonstrating a statistically significant improvement in overall survival (OS) in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC) compared to those patients treated with BSC alone. [More]
Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

Once-weekly Trulicity 0.75 mg shows promising results in Japanese patients with type 2 diabetes

Results from a new study of Japanese patients with type 2 diabetes showed once-weekly Trulicity 0.75 mg provided greater hemoglobin A1c (A1C) reduction compared to once-daily Victoza 0.9 mg after 52 weeks of treatment. Eli Lilly and Company will present these data at the 75th American Diabetes Association Scientific Sessions in Boston. [More]
Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Eisai Inc. announced today results from an investigational Phase 2 trial which showed that lenvatinib, when used in combination with everolimus, significantly extended progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) versus everolimus alone. [More]
Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD). [More]
Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck, known as MSD outside the U.S. and Canada, today announced an expanded collaboration to evaluate the efficacy and safety of talimogene laherparepvec, Amgen's investigational oncolytic immunotherapy, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in a Phase 1, open-label trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). [More]
New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

New clinical data demonstrating treatment options in Lilly's diabetes portfolio to be presented at ADA Scientific Sessions

New clinical data demonstrating the range of treatment options represented in Lilly's diabetes portfolio will be presented in 79 abstracts on June 5-9, at the 75th American Diabetes Association (ADA)® Scientific Sessions in Boston. [More]
Boehringer Ingelheim, University of Michigan partner to discover new medicines for diabetic nephropathy

Boehringer Ingelheim, University of Michigan partner to discover new medicines for diabetic nephropathy

Boehringer Ingelheim and the University of Michigan announce today that they have entered into a research collaboration focused on the discovery of new medicines for patients with diabetic nephropathy. [More]
Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen today announced that it will present data from multiple Kyprolis (carfilzomib) for Injection, BLINCYTO (blinatumomab), oprozomib and Nplate (romiplostim)‎ studies at the 20th Congress of the European Hematology Association taking place in Vienna, June 11 - 14, 2015. [More]
Debiotech agrees to acquire exclusive rights on iSense CGM technology for use with patch pumps

Debiotech agrees to acquire exclusive rights on iSense CGM technology for use with patch pumps

Debiotech of Switzerland and iSense CGM, Inc. of the US, announced today having entered into an Agreement under which Debiotech has the option to acquire the exclusive rights on the iSense CGM product and technology for use with patch pumps for diabetes therapy. Financial terms and conditions of the Agreement are not disclosed. [More]
NEFIGAN Trial of Nefecon for treatment of primary IgA nephropathy meets primary endpoint

NEFIGAN Trial of Nefecon for treatment of primary IgA nephropathy meets primary endpoint

Pharmalink AB, a specialty pharma company, today announces that the NEFIGAN Trial of Nefecon for the treatment of primary IgA nephropathy has fully met its primary efficacy endpoint at a planned interim analysis and been stopped early with respect to statistical analysis of the endpoint. [More]
Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

Amgen today announced that the European Commission approved a new use of Vectibix (panitumumab) as first-line treatment in combination with FOLFIRI for the treatment of adult patients with wild-type (WT) RAS metastatic colorectal cancer (mCRC). [More]
Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Amgen today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) of Kyprolis® (carfilzomib) for Injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. [More]
Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced its plans for the commercialization of SPRIX (ketorolac tromethamine) Nasal Spray and OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII. [More]
Study finds direct evidence of gadolinium deposition in neuronal tissues following contrast-enhanced MRI exams

Study finds direct evidence of gadolinium deposition in neuronal tissues following contrast-enhanced MRI exams

Mayo Clinic research finds direct evidence of gadolinium deposition in neuronal tissues following intravenous administration of gadolinium-based contrast agents used in MRI exams. The findings were recently published online in the journal Radiology. [More]
Egalet announces net revenues of $1.9 million for 2014

Egalet announces net revenues of $1.9 million for 2014

Egalet Corporation today reported financial results for the year ended December 31, 2014. [More]
Advertisement